The KMO Polyclonal Antibody (PAC043748) is a valuable tool for researchers studying the kynurenine 3-monooxygenase (KMO) enzyme, which plays a crucial role in the kynurenine pathway. This pathway is involved in the metabolism of tryptophan and has been implicated in various physiological and pathological processes, including neurodegenerative diseases, inflammation, and cancer.Raised in rabbits, this antibody exhibits high reactivity with human samples and has been validated for use in Western blot applications. It specifically binds to the KMO protein, enabling researchers to detect and analyze its expression in different cell types.
This makes it an ideal choice for studies in the fields of neuroscience, immunology, and oncology.The KMO enzyme has been identified as a promising therapeutic target for conditions such as Alzheimer's disease, Parkinson's disease, and certain types of cancer. By gaining a better understanding of KMO's function and regulation, researchers can develop novel treatment strategies that modulate the kynurenine pathway, paving the way for potential therapeutic interventions in these debilitating diseases.
Recombinant Human Kynurenine 3-monooxygenase protein (1-260AA)
Form:
Liquid
Storage Buffer:
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Purification Method:
Antigen Affinity Purified
Clonality:
Polyclonal
Isotype:
IgG
Conjugate:
Non-conjugated
Western blot. All lanes: KMO antibody at 10µg/ml + Mouse heart tissue. Secondary. Goat polyclonal to rabbit IgG at 1/10000 dilution. Predicted band size: 56, 55, 52 kDa. Observed band size: 56 kDa.
Immunohistochemistry of paraffin-embedded human breast cancer using PACO43748 at dilution of 1:100.
Background:
Catalyzes the hydroxylation of L-kynurenine (L-Kyn) to form 3-hydroxy-L-kynurenine (L-3OHKyn). Required for synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist and potential endogenous inhibitor of NMDA receptor signaling in axonal targeting, synaptogenesis and apoptosis during brain development. Quinolinic acid, may also affect NMDA receptor signaling in pancreatic β cells, osteoblasts, myocardial cells, and the gastrointestinal tract.
KMO: Catalyzes the hydroxylation of L-kynurenine (L-Kyn) to form 3-hydroxy-L-kynurenine (L-3OHKyn). Required for synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist and potential endogenous inhibitor of NMDA receptor signaling in axonal targeting, synaptogenesis and apoptosis during brain development. Quinolinic acid may also affect NMDA receptor signaling in pancreatic beta cells, osteoblasts, myocardial cells, and the gastrointestinal tract. Belongs to the aromatic-ring hydroxylase family. KMO subfamily. 3 isoforms of the human protein are produced by alternative splicing.Protein type: Oxidoreductase; Membrane protein, integral; Amino Acid Metabolism - tryptophan; Mitochondrial; EC 1.14.13.9; Membrane protein, multi-passChromosomal Location of Human Ortholog: 1q42-q44Cellular Component: cytosol; mitochondrial outer membraneMolecular Function: FAD binding; kynurenine 3-monooxygenase activity; NAD(P)H oxidase activityBiological Process: NAD metabolic process; response to salt stress; tryptophan catabolic process
UniProt Protein Details:
NCBI Summary:
This gene encodes a mitochondrion outer membrane protein that catalyzes the hydroxylation of L-tryptophan metabolite, L-kynurenine, to form L-3-hydroxykynurenine. Studies in yeast identified this gene as a therapeutic target for Huntington disease. [provided by RefSeq, Oct 2011]